Showing papers in "Blood in 2019"
••
University of Texas MD Anderson Cancer Center1, Johns Hopkins University2, City of Hope National Medical Center3, University of California, Davis4, Emory University5, Fred Hutchinson Cancer Research Center6, University of Washington7, Northwestern University8, Monash University9, AbbVie10, Genentech11, University of Colorado Denver12, Harvard University13
TL;DR: The novel combination of venetoclax with decitabine or azacitidine was effective and well tolerated in elderly patients with AML and achieved complete remission (CR) + CR with incomplete count recovery (CRi).
1,153 citations
••
TL;DR: The characteristic features of these new and modified entities as well as the results of recent molecular studies with diagnostic, prognostic, and/or therapeutic significance for the different types of primary cutaneous lymphomas are reviewed.
720 citations
••
TL;DR: Based on experience with anemia treatment in chronic kidney disease, critical illness, and cancer, finding the appropriate indications for the specific treatment of AI will require improved understanding and a balanced consideration of the contribution of anemia to each patient's morbidity and the impact of anemic treatment on the patient's prognosis in a variety of disease settings.
537 citations
••
Karolinska University Hospital1, St. Jude Children's Research Hospital2, Medical University of Warsaw3, Brigham and Women's Hospital4, Cincinnati Children's Hospital Medical Center5, Erasmus University Medical Center6, Charité7, University of Bristol8, Capital Medical University9, University of Hamburg10
TL;DR: In this article, the authors present expert opinions derived from an interdisciplinary working group on adult HLH, sponsored by the Histiocyte Society, to facilitate knowledge transfer between physicians caring for pediatric and adult patients with HLH with the aim to improve the outcome for adult patients affected by HLH.
511 citations
••
TL;DR: It is shown that GM-CSF neutralization with lenzilumab does not inhibit CART19 cell function in vitro or in vivo, and a novel approach to abrogate NI and CRS through GM- CSF neutralized, which may potentially enhance CAR-T cell function.
362 citations
••
University of Valencia1, Carlos III Health Institute2, Paris Diderot University3, Memorial Sloan Kettering Cancer Center4, Seattle Cancer Care Alliance5, Erasmus University Medical Center6, Heidelberg University7, University of Ulm8, University of Glasgow9, Shanghai Jiao Tong University10, Christian Medical College & Hospital11, Royal Prince Alfred Hospital12, University of São Paulo13, University of Texas MD Anderson Cancer Center14, Università Campus Bio-Medico15, University of Nottingham16, University of Rome Tor Vergata17
TL;DR: This review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder APL differentiation syndrome, QT prolongation, and other all-trans retinoic acid- and ATO-related toxicities.
358 citations
••
TL;DR: The role of basic aspects of coagulation and α-thrombin in promoting thromboinflammatory responses is focused on and insights gained from clinical trials on the effects of various inhibitors ofCoagulation on thrombosis with associated inflammation are discussed.
355 citations
••
TL;DR: The mechanisms of NET formation are discussed, as well as the apparent paradoxical role of neutrophils and NETs in host defense, chronic inflammation, and tissue disrepair.
318 citations
••
TL;DR: This review discusses neutrophil polarization and plasticity and the function of proinflammatory/anti-inflammatory and protumor/antitumor neutrophils in the tumor microenvironment and how neutrophIL with the ability to suppress T-cell activation fit into this paradigm.
305 citations
••
University of Chicago1, University of Pennsylvania2, Cleveland Clinic3, University of Rochester4, University of New Mexico5, St. Jude Children's Research Hospital6, Montefiore Medical Center7, Duke University8, University of South Florida9, Ohio State University10, City of Hope National Medical Center11, Stanford University12, Pennsylvania State University13, University of North Carolina at Chapel Hill14, State University of New York Upstate Medical University15, Fred Hutchinson Cancer Research Center16, Mayo Clinic17, Memorial Sloan Kettering Cancer Center18, Harvard University19
TL;DR: Use of a pediatric regimen for AYA patients with newly diagnosed ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls, and CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL.
251 citations
••
TL;DR: Patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy who might benefit from consolidation strategies such as allogeneic HCT are studied.
••
Memorial Sloan Kettering Cancer Center1, Cornell University2, University of Texas MD Anderson Cancer Center3, Harvard University4, University of Colorado Denver5, Northwestern University6, NewYork–Presbyterian Hospital7, Sarah Cannon Research Institute8, University of Texas Southwestern Medical Center9, Cleveland Clinic10, City of Hope National Medical Center11, University of Oxford12, Celgene13, Agios Pharmaceuticals14, Institut Gustave Roussy15, Université Paris-Saclay16
TL;DR: Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed and clearance of mutant-IDH2 clones was also associated with achievement of CR.
••
TL;DR: There remains a critical need to define the precise temporal and spatial mechanisms by which fibrinogen-directed inflammatory events may dictate the severity of tissue injury and coordinate the remodeling and repair events essential to restore normal organ function.
••
University of Sydney1, Concord Repatriation General Hospital2, Monash University, Clayton campus3, University of Texas MD Anderson Cancer Center4, University of Western Australia5, Sir Charles Gairdner Hospital6, Westmead Hospital7, Royal Hobart Hospital8, University of Tasmania9, Mayo Clinic10, Princess Alexandra Hospital11, University of Queensland12, North Shore Hospital13
TL;DR: Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities, and definition of the maximum tolerated dose (part 1).
••
TL;DR: A phase 2 hypothesis-generating trial to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls.
••
City of Hope National Medical Center1, University of Bologna2, University of Texas MD Anderson Cancer Center3, Harvard University4, Jewish General Hospital5, University of Manchester6, Institut Gustave Roussy7, Uppsala University8, Fujita Health University9, University of Cologne10, Merck & Co.11, University of Miami12
TL;DR: Results confirmed the effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL.
••
TL;DR: Emicizumab prophylaxis has been shown to be a highly effective novel medication for children with hemophilia A and inhibitors and two of 88 participants developed antidrug antibodies (ADAs) with neutralizing potential, ie, associated with decreased emicIZumab plasma concentrations.
••
TL;DR: Investigating whether blocking BCMA cleavage by small molecule γ-secretase inhibitors (GSIs) could augment BCMA-targeted CAR-T cell therapy found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion.
••
[...]
TL;DR: A review of the recent progress in myelodysplastic syndromes (MDS) genetics can be found in this paper, where a comprehensive registry of driver mutations recurrently found in a recognizable fraction of MDS patients has been revealed.
••
TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.
••
TL;DR: In conclusion, ravulizumab given every 8 weeks achieved noninferiority compared with eculizumAB given every 2 weeks for all efficacy end points, with a similar safety profile.
••
TL;DR: It was found that lower platelet counts at time of CAR T-cell infusion were associated with more severe neurotoxicity, and high pretreatment lactate dehydrogenase was frequently encountered in lymphoma patients with grade 3-4 neurotoxicity and correlated negatively with progression-free survival.
••
TL;DR: Patients with PNH may be safely and effectively switched from labeled-dose eculizumab administered every 2 weeks to ravulizumabs administered every 8 weeks, and no meningococcal infections or discontinuations due to adverse events occurred.
••
TL;DR: Previously-unrecognized evidence is presented that TNF- critically regulates megakaryocytes resident in the bone marrow niche and aging-associated platelet hyperreactivity and thrombosis and age-dependent metabolic profiles that may differentially poise platelets for activation.
••
TL;DR: The contention that early intervention with the use of tocilizumab and/or corticosteroids in subjects with early signs of CRS is without negative impact on anti-tumor potency of CD19CAR T cells is supported.
••
National Marrow Donor Program1, Center for International Blood and Marrow Transplant Research2, Georgetown University3, Memorial Sloan Kettering Cancer Center4, Cornell University5, Stanford University6, Naval Medical Research Center7, University of Chicago8, University of California, San Francisco9
TL;DR: The National Marrow Donor Program and the Center for International Blood and Marrow Transplant Research, jointly with the NMDP Histocompatibility Advisory Group, provide evidence-based guidelines for optimal selection of unrelated donors and cord blood units.
••
TL;DR: This review will focus on recent insights into how the liver senses body iron levels and coordinates this with other signals to regulate hepcidin production and systemic iron homeostasis.
••
TL;DR: The data supports the safety of CD19-specific CAR T cell therapy for R/R B-ALL and suggest that dose intensity of conditioning chemotherapy and minimal pre-treatment disease burden have a positive impact on response without a negative effect on toxicity.
••
TL;DR: An institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel shows no patient experienced >grade 1 neurotoxicity and no patient required tocilizumab or steroids for CAR-T mediated toxicities.
••
Ohio State University1, University of California, Irvine2, Hofstra University3, Vanderbilt University4, Stanford University5, Peter MacCallum Cancer Centre6, Royal North Shore Hospital7, Medical University of Vienna8, University of Rochester Medical Center9, NewYork–Presbyterian Hospital10, University of California, San Diego11, Beaumont Hospital12, University of Texas MD Anderson Cancer Center13, Harvard University14
TL;DR: Long-term follow-up of patients treated in RESONATE provides support for sustained efficacy and safety of ibrutinib in relapsed/refractory CLL and consideration of study provisions that allow crossover to investigational therapy when benefit has been clearly demonstrated.